PFN1 Gene Polymorphisms and the Bone Mineral Density Response to Alendronate Therapy in Postmenopausal Chinese Women with Low Bone Mass.

ABSTRACT:

Purpose

Alendronate is a widely used anti-osteoporotic drug. PFN1 gene is a newly identified early-onset Paget's disease pathogenic gene. The purpose of this study is to study whether the genetic variations in this gene affect the clinical efficacy of alendronate in postmenopausal Chinese women with low bone mass.

Patients and methods

Seven single nucleotide polymorphisms in PFN1 gene were genotyped. A total of 500 postmenopausal women with osteoporosis or osteopenia were included. All participants were treated with weekly alendronate 70 mg for 12 months. A total of 466 subjects completed the follow-up. Bone mineral density (BMD) of lumbar spine, femoral neck and total hip were measured at baseline and after treatment.

Results

After 12 months of treatmen

SUBMITTER: Zhao J 

PROVIDER: S-EPMC8711734 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature